J&J Opens Houston Incubator With 21 Startups, 12 Biopharma Firms
This article was originally published in Scrip
Johnson & Johnson Innovation LLC, the big pharma's early-stage company accelerator and partnership negotiator, opened its fifth US incubator to house and support startup firms with 21 tenants, including a dozen therapeutics developers, in the Houston, Texas facility.
You may also be interested in...
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.